Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-digoxin polyclonal antibody - AMAG Pharmaceuticals/Glenveigh Pharmaceuticals

Drug Profile

Anti-digoxin polyclonal antibody - AMAG Pharmaceuticals/Glenveigh Pharmaceuticals

Alternative Names: AMAG-423; Anti-digoxin-polyclonal-antibody-DigiFab; Anti-digoxin-polyclonal-antibody-DigiTAb; DIF; DigiBind; DigiFab; Digoxin Immune Fab; Digoxin Immune Fab (Ovine)

Latest Information Update: 27 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Glenveigh Pharmaceuticals; Protherics
  • Developer AMAG Pharmaceuticals; BTG Specialty Pharmaceuticals; Velo Bio
  • Class Antidotes; Immunoglobulin fragments; Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Poisoning; Preeclampsia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Poisoning
  • No development reported Preeclampsia

Most Recent Events

  • 23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.
  • 26 Sep 2022 No development reported - Phase-II/III for Preeclampsia in Spain, USA, South Africa, United Kingdom, Poland (IV)
  • 16 Nov 2020 AMAG Pharmaceuticals has been acquired by Covis Pharma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top